本刊讯为进一步推动我国医药产业结构调整和转型升级,近日国家食品药品监督管理总局公布了第一批过度重复药品品种目录,提醒社会投资方和相关企业,注意评估研发风险,慎重进行投资经营决策。国家食品药品监督管理总局通过全面筛查国内已上市药品和正在申报注册药品,遴选出相同活性成分、相同给药途径药品批准文号数量在500个以上的34个品种和相同活性成分、相同给药途径药品注册申请数量 In order to further promote the restructuring and transformation and upgrading of China's pharmaceutical industry, the State Food and Drug Administration recently announced the first batch of over-duplicate drug catalogs to remind social investors and related enterprises, pay attention to assess the risk of research and development, and prudent investment management decision making. State Food and Drug Administration through a comprehensive screening of domestic listed drugs and are declaring the registration of drugs, the same active ingredients selected, the same route of administration of drug approval number of more than 500 varieties of 34 varieties and the same active ingredients, the same to Drug application number of drug registration applications